Hub : Traits :

Fed-up feelings

640 significantly associated models · 86 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	2	23453834	25141538	4	2	3.2e-10	2.2e-10	3.0e-02	88	C2orf84 UBXN2A
2	3	48381826	51009435	21	1	5.1e-14	6.6e-13	1.9e-01	97	GPX1
3	3	135273949	137261517	4	1	7.5e-11	4.7e-10	6.2e-01	99	STAG1
4	3	149722394	151134540	1	1	4.1e-12	1.1e-05	3.7e-01	96	RP11-103G8.2
5	7	116660803	118207833	1	1	7.6e-08	5.5e-10	4.0e-04	68	CTTNBP2
6	8	8092025	11891593	12	1	6.0e-13	4.3e-11	2.3e-01	97	FAM86B3P
7	9	119768572	121177842	1	1	2.3e-07	3.3e-07	1.0e+00	100	TLR4
8	11	46010847	48285906	8	1	1.4e-11	5.7e-10	2.5e-02	87	ZNF408
9	11	63316786	64820283	2	1	1.5e-08	7.9e-08	2.5e-03	68	PPP1R14B
10	12	111154626	112582540	1	1	1.5e-07	9.7e-07	2.4e-01	94	SH2B3
11	14	74424938	76226003	5	2	2.5e-10	3.1e-11	8.3e-02	93	AREL1 DLST
12	17	42774693	45796313	19	1	5.2e-12	2.4e-11	1.0e+00	100	KANSL1-AS1
13	18	34614002	35378540	1	1	4.5e-09	2.3e-12	4.3e-05	66	CELF4
14	18	49172179	51753106	1	1	1.5e-07	6.1e-12	2.3e-06	53	DCC
15	19	32209988	33668090	2	1	3.9e-10	1.0e-09	1.0e+00	100	DPY19L3
16	20	2429222	3827309	1	1	1.7e-07	5.2e-05	2.2e-01	91	FASTKD5
17	20	44501458	44999958	1	1	1.1e-07	5.1e-07	1.0e-01	89	CD40

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	1.65	2	0	0.0	0.00	1.0e+00	DCC FAM86B3P
Depressed Affect (Nagel 2018)	16.33	16	12	26.7	0.98	9.8e-12	AREL1 C2orf84 CD40 CELF4 DCC DLST DPY19L3 FASTKD5 GPX1 KANSL1-AS1 RP11-103G8.2 SH2B3 STAG1 TLR4 UBXN2A ZNF408
Depression (Nagel 2018)	7.47	7	1	2.2	0.99	1.1e-05	CD40 DCC DPY19L3 KANSL1-AS1 STAG1 UBXN2A ZNF408
Intelligence (Savage-Jansen 2018)	3.91	3	2	4.4	0.00	1.0e+00	GPX1 KANSL1-AS1 STAG1
Neuroticism (Nagel 2018)	13.90	15	10	22.2	0.97	4.7e-09	AREL1 CD40 CELF4 CTTNBP2 DCC DLST DPY19L3 FASTKD5 GPX1 KANSL1-AS1 RP11-103G8.2 STAG1 TLR4 UBXN2A ZNF408
Schizophrenia (2018)	2.13	2	0	0.0	0.00	1.0e+00	DCC STAG1
Schizophrenia vs Biploar Disorder	1.83	1	0	0.0	0.00	1.0e+00	KANSL1-AS1
Worry (Nagel 2018)	6.79	5	4	8.9	0.98	2.6e-03	AREL1 DLST KANSL1-AS1 STAG1 ZNF408
Crohns Disease (2017)	2.98	2	1	2.2	0.00	1.0e+00	GPX1 PPP1R14B
Irritable Bowel Disease (IBD)	3.36	1	1	2.2	0.00	1.0e+00	GPX1
Ulcerative Colitis (UC)	2.36	1	1	2.2	0.00	1.0e+00	GPX1
Major Depression (MDD)	4.18	1	0	0.0	0.00	1.0e+00	GPX1
Reaction Time	3.43	1	1	2.2	0.00	1.0e+00	SH2B3
Verbal and Numeric Reasoning (VNR)	3.26	3	1	2.2	0.00	1.0e+00	GPX1 KANSL1-AS1 STAG1
Breast Cancer	1.80	2	1	2.2	0.00	1.0e+00	GPX1 KANSL1-AS1
Ovarian Cancer	3.05	1	1	2.2	0.00	1.0e+00	KANSL1-AS1
Prostate Cancer	2.04	1	0	0.0	0.00	1.0e+00	GPX1
Age at First Birth	3.94	1	1	2.2	0.00	1.0e+00	GPX1
Coronary Artery Disease (CAD)	2.59	1	0	0.0	0.00	1.0e+00	SH2B3
Crohns Disease (2012)	2.48	1	1	2.2	0.00	1.0e+00	GPX1
HDL Cholesterol	1.85	1	0	0.0	0.00	1.0e+00	DPY19L3
LDL Cholesterol	2.00	1	0	0.0	0.00	1.0e+00	SH2B3
Lupus	2.07	1	0	0.0	0.00	1.0e+00	FAM86B3P
Neuroticism (2016)	8.46	6	2	4.4	0.98	4.0e-04	AREL1 CELF4 FAM86B3P KANSL1-AS1 TLR4 ZNF408
Primary Biliary Cirrhosis	3.11	3	1	2.2	0.00	1.0e+00	KANSL1-AS1 PPP1R14B SH2B3
Rheumatoid Arthritis	3.16	2	1	2.2	0.00	1.0e+00	CD40 SH2B3
Schizophrenia (2014)	2.37	2	0	0.0	0.00	1.0e+00	FAM86B3P STAG1
Ulcerative Colitis	2.11	1	1	2.2	0.00	1.0e+00	GPX1
Blood Eosinophil Count	10.62	2	2	4.4	0.00	1.0e+00	KANSL1-AS1 SH2B3
Blood Platelet Count	2.37	5	4	8.9	-0.76	1.3e-01	AREL1 DLST KANSL1-AS1 PPP1R14B SH2B3
Blood Red Count	4.57	4	4	8.9	-0.24	7.6e-01	C2orf84 KANSL1-AS1 SH2B3 UBXN2A
Blood White Count	6.70	7	6	13.3	-0.96	7.6e-04	C2orf84 FASTKD5 GPX1 KANSL1-AS1 RP11-103G8.2 SH2B3 UBXN2A
Heel T-Score	3.03	5	2	4.4	-0.21	7.3e-01	AREL1 DLST KANSL1-AS1 PPP1R14B ZNF408
BMI	1.78	4	1	2.2	0.66	3.4e-01	DPY19L3 GPX1 PPP1R14B TLR4
Height	1.48	10	8	17.8	-0.54	1.1e-01	AREL1 C2orf84 CD40 CTTNBP2 DCC GPX1 KANSL1-AS1 SH2B3 STAG1 UBXN2A
Waist Hip Ratio (WHR)	3.10	6	3	6.7	-0.10	8.6e-01	C2orf84 GPX1 KANSL1-AS1 PPP1R14B STAG1 UBXN2A
Systolic Blood Pressure	5.17	6	5	11.1	-0.68	1.4e-01	AREL1 GPX1 KANSL1-AS1 PPP1R14B SH2B3 ZNF408
Smoking Status	3.75	3	2	4.4	0.00	1.0e+00	CTTNBP2 GPX1 PPP1R14B
Allergy or Eczema	1.16	1	0	0.0	0.00	1.0e+00	CD40
Cardiovascular Disease	3.57	3	2	4.4	0.00	1.0e+00	PPP1R14B SH2B3 ZNF408
Hypothyroidism (self reported)	8.14	2	2	4.4	0.00	1.0e+00	PPP1R14B SH2B3
Type 2 Diabetes (T2D) (2018)	1.64	1	0	0.0	0.00	1.0e+00	SH2B3
Lung FEV1/FVC ratio	1.97	5	2	4.4	-0.69	1.9e-01	AREL1 CTTNBP2 DLST GPX1 KANSL1-AS1
Lung FVC	3.96	5	3	6.7	-0.59	3.0e-01	DCC GPX1 KANSL1-AS1 SH2B3 UBXN2A
Neuroticism	13.02	14	10	22.2	0.97	1.1e-08	AREL1 C2orf84 CD40 CELF4 CTTNBP2 DLST DPY19L3 FASTKD5 GPX1 KANSL1-AS1 STAG1 TLR4 UBXN2A ZNF408
Hair Pigment	0.20	2	1	2.2	0.00	1.0e+00	KANSL1-AS1 SH2B3
Tanning	0.39	2	0	0.0	0.00	1.0e+00	AREL1 SH2B3
Hand grip strength (left)	2.48	2	2	4.4	0.00	1.0e+00	AREL1 KANSL1-AS1
Number of treatments/medications taken	5.33	4	4	8.9	0.60	4.0e-01	AREL1 DLST GPX1 SH2B3
Sensitivity / hurt feelings	6.44	4	1	2.2	0.92	8.1e-02	CELF4 FAM86B3P KANSL1-AS1 STAG1
Frequency of depressed mood in last 2 weeks	9.16	5	1	2.2	0.99	1.3e-03	FAM86B3P KANSL1-AS1 STAG1 UBXN2A ZNF408
Relative age of first facial hair	3.46	1	1	2.2	0.00	1.0e+00	KANSL1-AS1
Systolic blood pressure, automated reading	4.98	6	4	8.9	-0.57	2.4e-01	AREL1 FAM86B3P GPX1 KANSL1-AS1 SH2B3 ZNF408
Medication: Co-codamol	2.54	1	0	0.0	0.00	1.0e+00	GPX1
Pack years adult smoking proportion	2.82	2	0	0.0	0.00	1.0e+00	CELF4 GPX1
Impedance of leg (right)	2.48	6	2	4.4	-0.25	6.3e-01	AREL1 FAM86B3P GPX1 KANSL1-AS1 STAG1 UBXN2A
Leg fat-free mass (left)	1.58	3	1	2.2	0.00	1.0e+00	FAM86B3P GPX1 SH2B3
Trunk fat percentage	2.52	6	3	6.7	0.61	2.0e-01	AREL1 C2orf84 DPY19L3 GPX1 KANSL1-AS1 UBXN2A
Hand grip strength (right)	1.76	1	1	2.2	0.00	1.0e+00	KANSL1-AS1
Townsend deprivation index at recruitment	2.40	1	0	0.0	0.00	1.0e+00	CTTNBP2
Current tobacco smoking	3.23	2	0	0.0	0.00	1.0e+00	CELF4 CTTNBP2
Frequency of unenthusiasm / disinterest in last 2 weeks	7.60	4	0	0.0	0.98	1.5e-02	DCC GPX1 STAG1 UBXN2A
Relative age voice broke	2.69	1	1	2.2	0.00	1.0e+00	KANSL1-AS1
Taking other prescription medications	5.62	5	3	6.7	0.58	3.1e-01	AREL1 DLST GPX1 PPP1R14B SH2B3
Age when periods started (menarche)	1.87	1	1	2.2	0.00	1.0e+00	GPX1
Heel bone mineral density (BMD) T-score, automated (left)	3.79	2	2	4.4	0.00	1.0e+00	FAM86B3P ZNF408
Qualifications: CSEs or equivalent	1.57	1	0	0.0	0.00	1.0e+00	GPX1
High blood pressure	4.11	3	3	6.7	0.00	1.0e+00	FAM86B3P SH2B3 ZNF408
Stomach or abdominal pain in last month	2.56	1	0	0.0	0.00	1.0e+00	STAG1
Medication: Atenolol	2.84	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Levothyroxine sodium	7.31	3	2	4.4	0.00	1.0e+00	FAM86B3P PPP1R14B SH2B3
Sitting height	2.66	5	4	8.9	-0.81	9.5e-02	C2orf84 DCC KANSL1-AS1 UBXN2A ZNF408
Body mass index (BMI)	3.02	4	3	6.7	0.46	5.4e-01	DPY19L3 FAM86B3P GPX1 STAG1
Impedance of leg (left)	2.58	6	4	8.9	-0.23	6.5e-01	AREL1 FAM86B3P GPX1 KANSL1-AS1 STAG1 UBXN2A
Leg predicted mass (left)	1.61	3	1	2.2	0.00	1.0e+00	FAM86B3P GPX1 SH2B3
Trunk fat mass	2.05	3	2	4.4	0.00	1.0e+00	DPY19L3 GPX1 KANSL1-AS1
Waist circumference	1.80	2	2	4.4	0.00	1.0e+00	DPY19L3 GPX1
Past tobacco smoking	3.26	2	0	0.0	0.00	1.0e+00	CTTNBP2 SH2B3
Alcohol usually taken with meals	3.52	2	2	4.4	0.00	1.0e+00	CELF4 CTTNBP2
Nervous feelings	6.17	6	3	6.7	0.99	3.3e-04	AREL1 DLST FAM86B3P KANSL1-AS1 STAG1 ZNF408
Frequency of tenseness / restlessness in last 2 weeks	7.92	5	3	6.7	0.98	4.2e-03	GPX1 KANSL1-AS1 STAG1 UBXN2A ZNF408
Hearing difficulty/problems with background noise	2.35	2	0	0.0	0.00	1.0e+00	KANSL1-AS1 ZNF408
Hair/balding pattern: Pattern 2	1.79	1	0	0.0	0.00	1.0e+00	KANSL1-AS1
Forced vital capacity (FVC)	3.43	2	2	4.4	0.00	1.0e+00	GPX1 KANSL1-AS1
Heel bone mineral density (BMD) T-score, automated (right)	4.23	2	2	4.4	0.00	1.0e+00	FAM86B3P ZNF408
Ever unenthusiastic/disinterested for a whole week	4.05	1	0	0.0	0.00	1.0e+00	KANSL1-AS1
Qualifications: None of the above	4.14	2	1	2.2	0.00	1.0e+00	CELF4 GPX1
Heart attack	1.77	1	0	0.0	0.00	1.0e+00	SH2B3
Pain all over the body in last month	1.97	1	0	0.0	0.00	1.0e+00	GPX1
Fluid intelligence score	2.82	2	2	4.4	0.00	1.0e+00	GPX1 STAG1
Illnesses of siblings	2.22	1	0	0.0	0.00	1.0e+00	SH2B3
Neuroticism score	14.47	14	9	20.0	0.98	3.3e-09	AREL1 C2orf84 CD40 CELF4 CTTNBP2 DLST DPY19L3 FAM86B3P GPX1 KANSL1-AS1 STAG1 TLR4 UBXN2A ZNF408
Weight	1.74	4	1	2.2	0.57	4.3e-01	DPY19L3 FAM86B3P GPX1 SH2B3
Impedance of arm (right)	3.47	4	4	8.9	-0.53	4.7e-01	FAM86B3P GPX1 KANSL1-AS1 STAG1
Arm fat percentage (right)	2.25	3	2	4.4	0.00	1.0e+00	DPY19L3 FAM86B3P GPX1
Trunk fat-free mass	1.91	5	1	2.2	0.49	4.0e-01	CD40 GPX1 SH2B3 UBXN2A ZNF408
Hip circumference	1.96	5	2	4.4	0.41	4.9e-01	DPY19L3 FAM86B3P GPX1 PPP1R14B SH2B3
Alcohol intake versus 10 years previously	2.77	1	0	0.0	0.00	1.0e+00	GPX1
Father's age at death	4.57	2	1	2.2	0.00	1.0e+00	GPX1 SH2B3
Worrier / anxious feelings	8.08	6	5	11.1	0.99	1.3e-04	AREL1 DLST FAM86B3P KANSL1-AS1 STAG1 TLR4
Frequency of tiredness / lethargy in last 2 weeks	7.31	5	1	2.2	0.98	3.4e-03	DCC GPX1 STAG1 UBXN2A ZNF408
Hair/balding pattern: Pattern 3	3.58	1	1	2.2	0.00	1.0e+00	KANSL1-AS1
Number of live births	1.70	1	0	0.0	0.00	1.0e+00	KANSL1-AS1
Forced expiratory volume in 1-second (FEV1)	4.37	5	2	4.4	0.09	8.8e-01	C2orf84 FAM86B3P GPX1 KANSL1-AS1 UBXN2A
Qualifications: A levels/AS levels or equivalent	4.87	2	1	2.2	0.00	1.0e+00	GPX1 KANSL1-AS1
Mouth/teeth dental problems: Dentures	2.48	2	0	0.0	0.00	1.0e+00	GPX1 STAG1
Medication: Ibuprofen (e.g. Nurofen)	2.92	2	0	0.0	0.00	1.0e+00	KANSL1-AS1 UBXN2A
Forced expiratory volume in 1-second (FEV1), Best measure	3.94	3	2	4.4	0.00	1.0e+00	GPX1 KANSL1-AS1 ZNF408
Impedance of arm (left)	3.74	5	4	8.9	-0.61	2.8e-01	FAM86B3P GPX1 KANSL1-AS1 SH2B3 STAG1
Arm fat mass (right)	2.31	3	3	6.7	0.00	1.0e+00	DPY19L3 FAM86B3P GPX1
Trunk predicted mass	1.90	5	1	2.2	0.51	3.9e-01	CD40 GPX1 SH2B3 UBXN2A ZNF408
Standing height	1.49	8	3	6.7	-0.41	3.1e-01	C2orf84 FAM86B3P GPX1 KANSL1-AS1 SH2B3 STAG1 UBXN2A ZNF408
Exposure to tobacco smoke at home	2.30	1	0	0.0	0.00	1.0e+00	GPX1
Tense / 'highly strung'	4.24	2	1	2.2	0.00	1.0e+00	AREL1 FAM86B3P
Seen doctor (GP) for nerves, anxiety, tension or depression	4.66	4	0	0.0	1.00	4.4e-03	AREL1 CELF4 CTTNBP2 ZNF408
Hair/balding pattern: Pattern 4	5.97	1	1	2.2	0.00	1.0e+00	KANSL1-AS1
Birth weight of first child	2.49	1	1	2.2	0.00	1.0e+00	SH2B3
Peak expiratory flow (PEF)	2.55	2	1	2.2	0.00	1.0e+00	FAM86B3P KANSL1-AS1
Ever highly irritable/argumentative for 2 days	3.52	1	0	0.0	0.00	1.0e+00	GPX1
Qualifications: O levels/GCSEs or equivalent	2.74	1	0	0.0	0.00	1.0e+00	GPX1
Medication: Paracetamol	4.30	2	1	2.2	0.00	1.0e+00	GPX1 KANSL1-AS1
Headache pain in last month	4.41	2	1	2.2	0.00	1.0e+00	KANSL1-AS1 TLR4
Medication for cholesterol, blood pressure or diabetes	2.39	1	1	2.2	0.00	1.0e+00	SH2B3
Gout (self-reported)	2.22	2	0	0.0	0.00	1.0e+00	PPP1R14B SH2B3
Hypothyroidism/myxoedema (self-reported)	7.79	3	2	4.4	0.00	1.0e+00	FAM86B3P PPP1R14B SH2B3
Birth weight	1.61	1	1	2.2	0.00	1.0e+00	SH2B3
High blood pressure (siblings)	1.78	1	0	0.0	0.00	1.0e+00	SH2B3
Forced vital capacity (FVC), Best measure	3.40	3	2	4.4	0.00	1.0e+00	GPX1 KANSL1-AS1 ZNF408
Body fat percentage	2.76	5	3	6.7	0.99	6.1e-04	AREL1 C2orf84 DPY19L3 GPX1 UBXN2A
Leg fat percentage (right)	3.81	6	3	6.7	0.61	2.0e-01	AREL1 C2orf84 DPY19L3 FAM86B3P GPX1 UBXN2A
Arm fat-free mass (right)	1.88	3	2	4.4	0.00	1.0e+00	FAM86B3P GPX1 SH2B3
Exposure to tobacco smoke outside home	4.22	1	1	2.2	0.00	1.0e+00	CTTNBP2
Comparative body size at age 10	1.42	1	1	2.2	0.00	1.0e+00	FAM86B3P
Number of full brothers	2.53	1	0	0.0	0.00	1.0e+00	GPX1
Worry too long after embarrassment	4.73	3	2	4.4	0.00	1.0e+00	FAM86B3P KANSL1-AS1 STAG1
Wheeze or whistling in the chest in last year	2.79	1	0	0.0	0.00	1.0e+00	GPX1
Age at first live birth	4.39	2	1	2.2	0.00	1.0e+00	CELF4 GPX1
Health satisfaction	2.55	1	0	0.0	0.00	1.0e+00	GPX1
Qualifications: College or University degree	5.54	5	3	6.7	-0.92	2.7e-02	CELF4 CTTNBP2 GPX1 KANSL1-AS1 PPP1R14B
Medication for pain relief, constipation, heartburn	4.60	3	1	2.2	0.00	1.0e+00	AREL1 GPX1 KANSL1-AS1
Neck or shoulder pain in last month	2.13	1	0	0.0	0.00	1.0e+00	GPX1
Medication: Blood pressure	3.19	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Allopurinol	2.09	2	0	0.0	0.00	1.0e+00	PPP1R14B SH2B3
Mean time to correctly identify matches	3.51	2	1	2.2	0.00	1.0e+00	SH2B3 ZNF408
Whole body fat mass	2.29	3	2	4.4	0.00	1.0e+00	DPY19L3 FAM86B3P GPX1
Leg fat mass (right)	2.86	3	3	6.7	0.00	1.0e+00	DPY19L3 FAM86B3P GPX1
Arm predicted mass (right)	1.99	3	3	6.7	0.00	1.0e+00	FAM86B3P GPX1 SH2B3
Alcohol intake frequency.	2.67	2	1	2.2	0.00	1.0e+00	DCC KANSL1-AS1
Comparative height size at age 10	2.00	4	3	6.7	-0.58	4.2e-01	DLST KANSL1-AS1 SH2B3 STAG1
Suffer from 'nerves'	5.46	4	2	4.4	1.00	7.8e-04	AREL1 DLST FAM86B3P ZNF408
Overall health rating	4.18	2	1	2.2	0.00	1.0e+00	GPX1 ZNF408
Age at last live birth	3.18	1	1	2.2	0.00	1.0e+00	GPX1
Leg pain on walking	2.84	1	0	0.0	0.00	1.0e+00	GPX1
Illness, injury, bereavement, stress in last 2 years	2.32	1	0	0.0	0.00	1.0e+00	CTTNBP2
Medication: Aspirin	2.53	1	0	0.0	0.00	1.0e+00	SH2B3
Hypertension (Self-reported)	3.95	3	3	6.7	0.00	1.0e+00	FAM86B3P SH2B3 ZNF408
Smoking status: Previous	2.77	1	0	0.0	0.00	1.0e+00	SH2B3
Whole body fat-free mass	1.81	5	2	4.4	0.43	4.7e-01	FAM86B3P GPX1 SH2B3 UBXN2A ZNF408
Leg fat-free mass (right)	1.62	3	1	2.2	0.00	1.0e+00	FAM86B3P GPX1 SH2B3
Arm fat percentage (left)	2.33	3	2	4.4	0.00	1.0e+00	DPY19L3 FAM86B3P GPX1
Handedness (chirality/laterality): Left-handed	1.76	1	0	0.0	0.00	1.0e+00	KANSL1-AS1
Mood swings	13.18	13	5	11.1	0.98	1.9e-09	AREL1 CD40 CELF4 CTTNBP2 DCC DLST DPY19L3 FAM86B3P GPX1 KANSL1-AS1 STAG1 TLR4 ZNF408
Loneliness, isolation	7.55	5	0	0.0	1.00	1.1e-04	GPX1 KANSL1-AS1 SH2B3 STAG1 ZNF408
Qualifications: nursing, teaching	3.46	1	0	0.0	0.00	1.0e+00	GPX1
Mouth/teeth dental problems: Mouth ulcers	2.95	2	1	2.2	0.00	1.0e+00	KANSL1-AS1 SH2B3
Medication for cholesterol	3.24	1	1	2.2	0.00	1.0e+00	SH2B3
Illnesses of father: None of the above (group 1)	1.74	1	0	0.0	0.00	1.0e+00	SH2B3
Smoking status: Current	2.98	1	0	0.0	0.00	1.0e+00	CTTNBP2
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.55	1	1	2.2	0.00	1.0e+00	KANSL1-AS1
Whole body water mass	1.84	5	2	4.4	0.44	4.6e-01	FAM86B3P GPX1 SH2B3 UBXN2A ZNF408
Leg predicted mass (right)	1.63	4	1	2.2	0.30	7.0e-01	FAM86B3P GPX1 SH2B3 ZNF408
Arm fat mass (left)	2.23	3	3	6.7	0.00	1.0e+00	DPY19L3 FAM86B3P GPX1
Number of self-reported non-cancer illnesses	4.19	4	1	2.2	-0.99	8.5e-03	AREL1 PPP1R14B SH2B3 ZNF408
Average weekly champagne plus white wine intake	2.57	1	0	0.0	0.00	1.0e+00	KANSL1-AS1
Miserableness	12.19	12	6	13.3	0.99	3.0e-10	C2orf84 CD40 CELF4 CTTNBP2 DPY19L3 FAM86B3P GPX1 KANSL1-AS1 RP11-103G8.2 STAG1 UBXN2A ZNF408
Guilty feelings	9.89	7	4	8.9	0.95	9.4e-04	AREL1 C2orf84 DLST FAM86B3P GPX1 KANSL1-AS1 UBXN2A
Financial situation satisfaction	3.19	1	1	2.2	0.00	1.0e+00	GPX1
Medication: Blood pressure	3.97	3	1	2.2	0.00	1.0e+00	KANSL1-AS1 SH2B3 ZNF408
Medication: Bendroflumethiazide	3.04	2	0	0.0	0.00	1.0e+00	FAM86B3P SH2B3
Medication: Paracetamol	4.28	2	1	2.2	0.00	1.0e+00	GPX1 KANSL1-AS1
Medication: Lisinopril	2.25	1	0	0.0	0.00	1.0e+00	ZNF408
Illnesses of father: High blood pressure	1.71	1	0	0.0	0.00	1.0e+00	SH2B3
Ever smoked	3.46	2	1	2.2	0.00	1.0e+00	CTTNBP2 SH2B3
Basal metabolic rate	1.74	4	2	4.4	0.57	4.3e-01	DPY19L3 FAM86B3P GPX1 SH2B3
Leg fat percentage (left)	3.76	6	3	6.7	0.60	2.1e-01	AREL1 C2orf84 DPY19L3 FAM86B3P GPX1 UBXN2A
Arm fat-free mass (left)	2.08	4	2	4.4	0.61	3.9e-01	DPY19L3 FAM86B3P GPX1 SH2B3
Average weekly beer plus cider intake	3.50	2	0	0.0	0.00	1.0e+00	CELF4 FAM86B3P
Irritability	6.69	5	2	4.4	0.99	1.6e-03	AREL1 CELF4 FAM86B3P KANSL1-AS1 TLR4
Age started oral contraceptive pill	2.11	1	0	0.0	0.00	1.0e+00	GPX1
Diastolic blood pressure, automated reading	5.80	4	3	6.7	-0.70	3.0e-01	FAM86B3P GPX1 SH2B3 ZNF408
Vascular/heart problems diagnosed by doctor	3.99	3	2	4.4	0.00	1.0e+00	FAM86B3P SH2B3 ZNF408
Pain experienced in last month	3.84	2	1	2.2	0.00	1.0e+00	GPX1 KANSL1-AS1
Heart attack/myocardial infarction (self-reported)	1.80	1	0	0.0	0.00	1.0e+00	SH2B3
Pack years of smoking	2.48	2	0	0.0	0.00	1.0e+00	CELF4 GPX1
Impedance of whole body	3.40	6	4	8.9	-0.36	4.9e-01	AREL1 FAM86B3P GPX1 KANSL1-AS1 STAG1 UBXN2A
Leg fat mass (left)	2.84	3	3	6.7	0.00	1.0e+00	DPY19L3 FAM86B3P GPX1
Arm predicted mass (left)	2.05	4	2	4.4	0.61	3.9e-01	CD40 FAM86B3P GPX1 SH2B3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	12	0.344	1.9
GTEx	Adipose Visceral Omentum	11	0.540	2.0
GTEx	Adrenal Gland	8	0.549	1.9
GTEx	Artery Aorta	13	0.437	1.9
GTEx	Artery Coronary	11	0.930	2.1
GTEx	Artery Tibial	14	0.372	1.9
GTEx	Brain Caudate basal ganglia	7	0.761	2.0
GTEx	Brain Cerebellar Hemisphere	11	0.739	1.9
GTEx	Brain Cerebellum	12	0.605	1.9
GTEx	Brain Cortex	8	0.773	2.0
GTEx	Brain Frontal Cortex BA9	8	0.866	2.1
GTEx	Brain Hippocampus	4	0.763	2.0
GTEx	Brain Hypothalamus	6	1.017	2.0
GTEx	Brain Nucleus accumbens basal ganglia	7	0.809	1.9
GTEx	Brain Putamen basal ganglia	6	0.962	2.0
GTEx	Breast Mammary Tissue	9	0.456	2.0
GTEx	Breast Mammary Tissue (Male)	7	0.587	1.8
GTEx	Breast Mammary Tissue (Female)	9	0.547	1.9
GTEx	Cells EBV-transformed lymphocytes	9	0.632	2.0
GTEx	Cells Transformed fibroblasts	17	0.405	1.9
GTEx	Colon Sigmoid	12	0.821	2.0
GTEx	Colon Transverse	14	0.678	1.9
GTEx	Esophagus Gastroesophageal Junction	9	0.623	2.0
GTEx	Esophagus Mucosa	18	0.542	1.9
GTEx	Esophagus Muscularis	21	0.650	2.0
GTEx	Heart Atrial Appendage	11	0.697	1.9
GTEx	Heart Left Ventricle	9	0.588	2.0
GTEx	Liver	4	0.558	1.8
GTEx	Lung	17	0.592	1.9
GTEx	Muscle Skeletal	10	0.346	1.9
GTEx	Nerve Tibial	12	0.278	1.9
GTEx	Ovary	7	0.771	2.1
GTEx	Pancreas	9	0.551	1.9
GTEx	Pituitary	7	0.628	1.9
GTEx	Prostate	8	0.958	2.2
GTEx	Skin Not Sun Exposed Suprapubic	14	0.569	2.1
GTEx	Skin Sun Exposed Lower leg	16	0.440	2.0
GTEx	Small Intestine Terminal Ileum	5	1.085	2.1
GTEx	Spleen	10	0.709	2.0
GTEx	Stomach	11	0.757	2.0
GTEx	Testis	16	0.507	1.9
GTEx	Thyroid	15	0.375	1.9
GTEx	Uterus	8	1.411	2.3
GTEx	Vagina	7	1.102	2.1
GTEx	Whole Blood	6	0.301	1.8
METSIM	Adipose	4	0.087	1.6
NTR	Blood	7	0.291	1.7
ROSMAP	Brain Pre-frontal Cortex	15	0.342	1.9
YFS	Blood	4	0.087	1.6
CommonMind	Brain Pre-frontal Cortex	12	0.223	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	6	0.136	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	4	0.365	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	6	0.876	2.0
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.391	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	9	0.331	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	7	0.171	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	6	0.293	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	9	0.209	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	13	0.442	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	8	0.319	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.377	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	6	0.361	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	5	0.377	1.8
The Cancer Genome Atlas	Prostate Adenocarcinoma	10	0.216	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	3	0.434	1.8
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	5	0.297	1.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.7
The Cancer Genome Atlas	Thyroid Carcinoma	10	0.194	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.6